NEW YORK (
CHANGE IN RATINGS
was upgraded at Goldman Sachs from Sell. Valuation call, based on an $8 price target, Goldman said.
was upgraded at UBS to Buy from Neutral. $18 price target. Favorable risk/reward, UBS said.
was downgraded at Capstone Investments from Buy to Hold. Company lacks near-term visibility, Capstone said.
was upgraded at Wells Fargo to Market Perform. Business trends appear to be improving, Wells Fargo said.
was downgraded at Societe Generale from Buy to Hold. $47 price target. Company is seeing lower margins in North America, Societe Generale said.
was upgraded from Underweight to Neutral at JP Morgan. $52 price target. Stock has declined 29% since earnings, JP Morgan said.
was upgraded at CLSA from Outperform to Buy. Expect strong 2013 guidance from management, CLSA said. $30 price target.
was initiated with a Buy rating at Wunderlich. Valuation call, based on a $30 price target.
was upgraded at UBS to Buy from Neutral. $24 price target. Consolidated company creates scale and value creation potential, UBS said.
was upgraded at Citigroup to Neutral from Sell. $23.50 price target. Shares approaching appropriate valuation, Citi said.
was initiated with a Neutral rating at JP Morgan. $20 price target. Company lacks near-term catalysts, JP Morgan said.
was upgraded to Buy at TheStreet Ratings.
was initiated with a Buy rating at Deutsche Bank. $30 price target. Company is leveraged to strong secular growth markets, Deutsche said.
was downgraded at Morgan Stanley from Overweight to Equal-weight. $25 price target. Company is facing regulatory and competitive pressures, Morgan Stanley said.
was upgraded at Bank of America/Merrill Lynch to Buy. Valuation call, based on a $54 price target, BofA/Merrill said.
was downgraded at BMO Capital to Market Perform. $13 price target. GSK may drop its bid for the company, BMO Capital said.
Hyatt Hotels Corp.
was downgraded to Hold at TheStreet Ratings.
was upgraded at Sterne Agee. $17 price target. Estimates were also increased, as the company should perform better over the coming quarters, Sterne Agee said.
National Oilwell Varco
was upgraded at Societe Generale from Hold to Buy. $85 price target. Stock has underperformed its peers of late, Societe Generale said.
was initiated with an Outperform rating at Bernstein. $74 price target. Carfilzomib should ultimately help drive the company toward profitability, Bernstein said.
was upgraded from Neutral to Buy at Bank of America/Merrill Lynch. $115 price target. Stock has pulled back, and the company should see lower raw material costs, BofA/Merrill said.
was downgraded at JP Morgan from Overweight to Neutral. $26 price target. Valuation call, as the stock is already up 61% on the year, JP Morgan said.
was upgraded to Neutral from Sell at UBS. $54 price target. Stock is now near its fair price, UBS said.
was upgraded at Wells Fargo from Market Perform to Outperform. Actavis acquisition should create higher earnings power, Wells said.
STOCK COMMENTS / EPS CHANGES
numbers were increased at Piper Jaffray. Company boosted its guidance, Piper Jaffray said. Overweight rating and new $24 price target.
numbers were lowered at Citigroup. Shares are now seen reaching $180. Estimates were also lowered as secondary absorbed significant demand and few near-term catalysts, Citi said.
was added to Select List at Stifel Nicolaus. Acquisitions should help boost growth, Stifel Nicolaus said. $71 price target.
numbers were cut at BMO. Estimates were reduced through 2013. Company is leveraged to weaker equity market performance, BMO said. Market Perform rating.
estimates, price target were raised at Sterne Agee. Estimates were boosted through 2014. Company is seeing favorable sales trends, Sterne Agee said. Buy rating and new $85 price target.
numbers were raised at Sterne Agee. Shares are now seen reaching $33. Estimates were also increased, as management appears to be turning the business around, Sterne Agee said. Buy rating.
numbers were lowered at Jefferies. Shares are now seen reaching $46. Estimates were also lowered on skepticism over growth projects, Jefferies said. Hold rating.
estimates, price target were reduced at Credit Suisse. Shares are now seen reaching $30. Estimates were also cut, given the company's new guidance, Credit Suisse said. Neutral rating.
estimates, price target were reduced at BMO Capital. Shares are now seen reaching $72. Company is seeing lower volume and rising input costs, BMO Capital said. Market Perform rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.